First Tracks Biotherapeutics TRAX
NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) Cash & Equivalents (2024 - 2026)

Updated

First Tracks Biotherapeutics (TRAX) reported Cash & Equivalents of $155.63 million for Q3 2026, down 7.4% from the prior quarter.

Analysis

First Tracks Biotherapeutics (TRAX) Cash & Equivalents (2024 - 2026) Analysis & Trends

At the end of FY2025, First Tracks Biotherapeutics posted Cash & Equivalents of $238.2 million, up 93.5% from FY2024.

  • By year, Cash & Equivalents came in at $123.08 million in FY2024.
  • The Q3 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q4 2024.
  • Per Business Quant data, the three quarters before Q3 2026 came in at $168.02 million (Q2 2026), $248.47 million (Q1 2026) and $238.2 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 4.89 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 16.91 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 10.77 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 9.55 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - 400.00 Mn
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 7.94 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 6.44 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 1.82 Bn
10 First Tracks Biotherapeutics 1.66 Bn 740.14 Mn - 155.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 155.63 Mn
Jun 30, 2026 168.02 Mn
Mar 31, 2026 248.47 Mn
Dec 31, 2025 238.20 Mn
Dec 31, 2024 123.08 Mn
API Access

First Tracks Biotherapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=TRAX&period=max&api_key=YOUR_API_KEY